Real-world Experience in Managing Atrial Fibrillation in Patients with Renal Impairment; Rivaroxaban versus Warfarin

BACKGROUND: The use of rivaroxaban in patients with atrial fibrillation (AF) and chronic kidney disease (CKD) poses the risk of over- or underdosing. We aimed to compare rivaroxaban and warfarin in AF patients with moderate and severe renal impairment. METHODS: This retrospective study was conducted...

Descripción completa

Detalles Bibliográficos
Autores principales: Albabtain, Monirah Abdulrahman, Alanazi, Zaid Dakheel, Al-Mutairi, Nawaf Hamoud, Alyafi, Ola, Albanyan, Raneem, Arafat, Amr A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424750/
https://www.ncbi.nlm.nih.gov/pubmed/37584025
http://dx.doi.org/10.4103/heartviews.heartviews_117_22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424750/
https://www.ncbi.nlm.nih.gov/pubmed/37584025
http://dx.doi.org/10.4103/heartviews.heartviews_117_22

Ejemplares similares